Lucius Pharmaceuticals has successfully launched lorlatinib, a targeted therapy for lung cancer, especially for patients with non-small cell lung cancer with ALK gene mutations. The drug has been licensed and certified by the Lao government and is recognized in many countries and regions around the world, providing more treatment options for cancer patients.
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: